Provided by Tiger Fintech (Singapore) Pte. Ltd.

GRI BIO INC

1.82
-0.1300-6.67%
Post-market: 1.880.0600+3.30%19:59 EDT
Volume:243.36K
Turnover:448.23K
Market Cap:3.90M
PE:-0.03
High:2.01
Open:2.00
Low:1.72
Close:1.95
Loading ...

Company Profile

Company Name:
GRI BIO INC
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
4
Office Location:
2223 Avenida de la Playa,Suite 208,LA Jolla,California,United States
Zip Code:
92037
Fax:
- -
Introduction:
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.

Directors

Name
Position
W. Marc Hertz
President, Chief Executive Officer and Director
David Szekeres
Chair of the Board and Director
Camilla V. Simpson
Director
David Baker
Director
Roelof Rongen
Director

Shareholders

Name
Position
W. Marc Hertz
President, Chief Executive Officer and Director
Leanne Kelly
Chief Financial Officer
Albert Agro
Chief Medical Officer
Vipin Kumar Chaturvedi
Chief Scientific Officer